tbuckley/cabot-search huggingface dataset:
Aids to Bacteriology.
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Maintenance Hemodialysis
Authors: A. Peter Lundin
Journal: JAMA (1980)

In a retrospective analysis of maintenance dialysis (MD) in a relatively homogeneous population of 24 patients (18 men, six women) who first received MD between 1964 and 1968 and who were initially free of other complicating diseases, we have confirmed that age at initiation of dialysis, sustained hypertension, and elevated calcium-phosphate product are significant risk factors for cardiovascular mortality. In patients without these risk factors sepsis has become the major cause of death, accounting for five (35.7%) of 14 deaths. The limit for long-term survival in an MD patient in whom the well-recognized risk factors are prevented or controlled is not yet apparent. (<i>JAMA</i>244:38-40, 1980)
Essentials of Physics.
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
IS CHILD HOMICIDE LEGALIZED?
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lanreotide depot/autogel (LAN) in pancreatic neuroendocrine tumors (pNETs): A subgroup analysis from the CLARINET study.
Authors: Alexandria T. Phan, Martyn E. Caplin, Marianne E. Pavel, Jaroslaw B Cwikla, Markus Raderer, Eva Sedlackova, Guillaume Cadiot, Edward M. Wolin, Jaume Capdevila, Lucy Wall, Guido Rindi, Alison Langley, Edda Gomez-Panzani, Philippe B. Ruszniewski
Journal: Journal of Clinical Oncology (2015)

e15178 Background: The prognosis for patients with metastatic pNETs is generally poor and current treatment options can be complicated by safety considerations. In CLARINET, progression-free survival (PFS) was significantly prolonged with the somatostatin analog LAN 120 mg vs. placebo in patients with metastatic grade 1 or 2 (Ki-67 < 10%) non-functioning intestinal and pNETs (hazard ratio [HR] for progressive disease [PD]/death: 0.47 [95% CI: 0.30, 0.73]. Here, we more fully characterize treatment effects in the pNET subgroup. Methods: CLARINET was a 96-week randomized double-blind trial. Patients received LAN 120 mg or placebo every 4 weeks, administered by deep subcutaneous injection (NCT00353496). Subgroup analyses were undertaken to investigate only the consistency of treatment effects as the study was not otherwise designed or powered for such analyses. Results: 91 patients with pNETs received LAN (n = 42) or placebo (n = 49). At baseline, mean age was 64 years in both groups; overall, 37% had hepatic tumor loads > 25%, 95% had stable disease, 77% had received no previous treatment, and 38% had undergone previous surgery on the tumor. Median PFS in the pNET subgroup was not reached at study end with LAN vs. 12.1 months [95% CI: 9.4, 18.3] with placebo (HR for PD/death: 0.58 [0.32, 1.04]). (Median PFS for lanreotide at first planned analysis in the open-label extension study was 29.7 months [12.0, 32.4].) Incidence of adverse events (AEs) in the core study was 88% with both LAN and placebo; the most common AE was diarrhea (lanreotide, 43%; placebo, 37%). Treatment-related AEs occurred in 55% of the LAN group and 24% of the placebo group. Serious AEs (SAEs) occurred in 29% vs. 43%, respectively; only three of these patients had treatment-related SAEs (two with LAN, one with placebo). Two patients in each group had AEs leading to withdrawal. Conclusions: The evidence in the pNET subgroup suggesting antitumor effects, together with the favorable long-term safety profile, support a positive benefit–risk profile for LAN as a first-line treatment for pNETs. Clinical trial information: NCT00353496.
Author's reply
Authors: K. Eberhardt
Journal: Annals of the Rheumatic Diseases (1996)

Associations of HLA-DRB and HLA-DRQ genes with two and five year outcomes in rheumatoid arthritisWe were interested in the results of the longitudinal study by Eberhardt and colleagues,' who examined the relationship between HLA-DRB and HLA-DRQ genes and outcomes in rheumatoid arthritis.Their results, showing a lack of relationship between HLA-DQ variants and articular disease severity, are in keeping with the results of our previous cross-sectional study that showed no influence of HILA-DQ variants on articular disease severity, in addition to demonstrating a definite re- lationship between homozygosity for HLA- DR4 and severity of articular disease.
Trauma systems. A model for regionalized care
Authors: D. Trunkey
Journal: JAMA (1995)

Although trauma centers have been present in the United States since 1966, trauma systems are relatively new. In this issue ofThe Journal, Bazzoli et al<sup>1</sup>present an update on the progress of trauma system development in the United States. Their report represents an extension of a previous article by West et al.<sup>2</sup>In addition to reviewing the original eight trauma system criteria of West and colleagues, the current report expands on the original study and provides a more sophisticated analysis of trauma systems and their development. Bazzoli et al show that since the publication of the report by West et al the number of complete trauma systems in the United States has increased from a relatively abysmal two complete systems in 1987 to five complete systems in 1993. See also p 395. One of the reasons for writing this progress report is the contention by the authors
Yellow Fever.
Authors: R. Cleary
Journal: JAMA (1889)

<h3>Audi Alteram Partem.</h3> <i>To the Editor:</i>—I have just read a letter inThe Journalfor July 27, last, from S. Paulo, Brazil, about the yellow fever in Santas, Campinas, and other smaller places in the same Province, with a great deal of interest and attention, as I am in the position to bear testimony to its correctness, having been all the time of the late epidemic practicing in Rio de Janeiro, which also suffered at the same period; so much so that the fatal year, 1889, will not soon be forgotten there. I was in correspondence with a medical friend in S. Paulo who gave me a very graphic picture of the state of affairs there, and I shrewdly suspect that he is the author of the letter inThe Journal; and as I know and esteem him as a competent observer of rigid impartiality, I think he will
The weight of an ounce
Authors: D. Satcher
Journal: JAMA (1995)

An ounce of prevention may seem a heavy load for the already overburdened, costly US health care system. But as health reformers somewhat wishfully argued during the 19th century, the road to wellness, although a lifelong journey, holds benefits along the way for those who seek prevention before they have to seek cure. The present generation has seen evidence of what those earlier reformers could only allege: that positive effects of prevention are sometimes just around the bend. The past two decades have witnessed dramatic declines in death rates for heart disease (51% reduction) and stroke (60% reduction).<sup>1,2</sup>These vast improvements in the nation's health are attributable to medical advances and nationwide changes in specific risk factors that were identified through epidemiologic research and addressed through population-based interventions.<sup>3-5</sup>. See also p 1123. Prevention works, then. But in this era of fiscal belt-tightening, the question arises, "At what cost?"
ORIGINAL ARTICLES.
Journal: JAMA (1887)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abortion Legislation
Authors: C. Paul Perry
Journal: JAMA (1983)

<h3>To the Editor.—</h3> Regarding the abortion legislation commentary by Milunsky and Glantz, what Milunsky and Glantz hail as a "grave danger" other physicians see as "a blessed hope." The current antiabortion proposals now before Congress offer the first opportunity since 1973 to return American medicine to its former high calling of life preservation. The authors present a number of real and imagined fears that would be created by the passage of these proposals. Their central argument stands clear: We mustn't return to an era without legal abortion because its use in practice and research, if denied, would throw us into another medical dark age. In medicine, we have allowed ourselves to be used as an instrument of social change. In the name of science, we have divorced technique from morality. Our skills have outstripped our ethics. As the Supreme Court ruled that the State had no compelling interest in the
THE ENIGMA OF HISTAMINE
Journal: JAMA (1961)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue Access Provided by Korea Advanced Inst of Science & Tech (KAIST) JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account
Guy's Hospital
Authors: H. N. Hardy
Journal: BMJ (1881)

<h3>Rationale and background</h3> Drowning is the first leading cause of death of Thai children under the age of 15 years old with the mortality per 100 000 population is between 9.3 and 11.5 (2004–2008). <h3>Objective</h3> To advocate child drowning prevention in Thailand. <h3>Methodology</h3> The magnitude of child drowning problems were proposed by mass media and communication especially with focusing on disseminated information that accompanied with important and attractive situation such as Songkran Festival and Loy Krathong Day. The advocated policy was to execute the public policy to be substantial. Implementation of the specific measure showed the interest of executives. <h3>Result</h3> The Ministry of Public Health and relevant agencies also assigned child drowning prevention measure such as established the child drowning prevention committees, the child swim able policy, the Day of Child Drowning Prevention, given the knowledge of child drowning prevention policy to the parents who take their children for vaccination in every hospital, child drowning surveillance and investigation, pilot project of model development of child drowning prevention, disseminated the information through mass media with supported from the private sector, and driving for adjusting the related legislation on child drowning prevention. After the implementation, the mortality of child drowning has decreased from 11.1 in 2006, to 9.8 and 9.3 in the years 2007 and 2008, respectively. <h3>Conclusion and recommendations</h3> As a result of wider dissemination of information and implementation of the child drowning prevention specific measure, executives have become a top priority national issue.
Cutaneous sarcoidosis in a patient with philadelphia‐positive chronic myelogenous leukemia treated with interferon‐α
Authors: Leonid L. Yavorkovsky, George Carrum, Suzanne Bruce, Philip L. McCarthy
Journal: American Journal of Hematology (1998)

A patient with Philadelphia-positive (Ph+) chronic myelogenous leukemia (CML) was diagnosed with cutaneous sarcoidosis after treatment with interferon-alpha (IFN-α). Following IFN-α dose reduction, the skin lesions disappeared. Few cases of sarcoidosis associated with IFN treatment have been reported, and only in one patient with pre-existing CML. Our patient was unique in that (1) the sarcoidosis was induced by the IFN-α treatment alone, (2) it developed de novo, and (3) it was confined to the skin. Am. J. Hematol. 58:80–81, 1998. © 1998 Wiley-Liss, Inc.
Watchful Waiting versus Immediate Treatment for Mild Hepatitis C
Journal: Annals of Internal Medicine (2000)

Summaries for Patients7 November 2000Watchful Waiting versus Immediate Treatment for Mild Hepatitis CSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-133-9-200011070-00003 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?Hepatitis C virus can lead to severe liver disease, but not everyone with this infection develops liver problems. Drugs to treat hepatitis C can cause side effects, are only partly effective, and are expensive. The effects of hepatitis C on the liver begin with inflammation of the liver (hepatitis) and progress to scarring (fibrosis), then cirrhosis (severe fibrosis with loss of liver function), and finally liver failure. If treatment starts too early, patients who would never develop liver failure might be exposed to expensive drugs with possible unpleasant ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “Watchful Waiting with Periodic Liver Biopsy versus Immediate Empirical Therapy for Histologically Mild Chronic Hepatitis C. A Cost-Effectiveness Analysis.” It is in the 7 November 2000 issue of Annals of Internal Medicine (volume 133, pages 665-675). The authors are JB Wong and RS Koff, for the International Hepatitis Interventional Therapy Group.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoWatchful Waiting with Periodic Liver Biopsy versus Immediate Empirical Therapy for Histologically Mild Chronic Hepatitis C: A Cost-Effectiveness Analysis John B. Wong and Raymond S. Koff Metrics 7 November 2000Volume 133, Issue 9Page: I-5KeywordsBiopsyCirrhosisDrugsHepatitisHepatitis CInflammationInterferonsLiverLiver fibrosisSimulation and modeling ePublished: 7 November 2000 Issue Published: 7 November 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
The histone demethylase LSD1/KDM1A promotes the DNA damage response
Authors: Nima Mosammaparast, Haeyoung Kim, Benoit Laurent, Yu Zhao, Hui Jun Lim, Mona C. Majid, Sebastian Dango, Yuying Luo, Kristina Hempel, Matthew E. Sowa, Steven P. Gygi, Hanno Steen, J. Wade Harper, Bruce Yankner, Yang Shi
Journal: The Journal of Experimental Medicine (2013)
HYPNOTISM AND MARRIAGE.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Misstated Terminology
Authors: Michael Joyner, Nigel Paneth
Journal: JAMA (2016)

tirely due to nongenomic advances.These advances in medicine include new and improved vaccines, folic acid to prevent neural tube defects, sleep position to prevent crib death, enhanced tobacco control, and implementation of screening programs for common cancers.These successful interventions were aimed at large segments of the population and produced measurable mortality benefits, often at remarkably low cost.By contrast, the accelerated drug discovery anticipated by the human genome project has not occurred; in fact, drug approvals by the US Food and Drug Administration have decreased during the past decade. 3Imatinib is touted as a model of targeted therapy, but chronic myeloid leukemia results from a consistent genetic defect that defines a clear therapeutic target distinctly different from the complex genetic factors associated with most cancers. 4Nor did imatinib stem from a massive data collection exercise, such as the national personalized medicine initiative.Basic research is critically important and fares best when it is driven by curiosity and unhampered by a top-down agenda.Progress, defined as increased knowledge, is inevitable.But progress in improving human health is never inevitable and is less likely to occur if the focus is on a narrow path that seeks to explain the causal determinants of disease largely, if not entirely, by examining gene variants. 5e do not doubt that genomic insights will ultimately translate into some useful therapies for small groups of people, but the limitations of the personalized medicine model as a broad medical strategy should not be ignored.
Tricyclic antidepressants--blood level measurements and clinical outcome: an APA Task Force report. Task Force on the Use of Laboratory Tests in Psychiatry
Journal: American Journal of Psychiatry (1985)

The Task Force examines the present status of studies investigating the relationship between blood plasma concentrations of tricyclic antidepressants and clinical outcome. It discusses some of the discrepancies that have developed among various antidepressant drugs and evaluates the clinical implications of the current status of blood level monitoring. The Task Force concludes that plasma level measurements of imipramine, desmethylimipramine, and nortriptyline are unequivocally clinically useful in certain situations, that these measurements are helpful in many situations, and that plasma level measurements are likely to grow in usefulness.